The global radioligand therapy market size was valued at USD 3.32 billion in 2025 and is projected to grow from USD 4.27 billion in 2026 to USD 31.76 billion by 2034, registering a CAGR of 28.52% during the forecast period from 2026 to 2034. North America dominated the radioligand therapy market with a market share of 48.17% in 2025.
The radioligand therapy market is driven by the increasing prevalence of hard-to-treat cancers, such as neuroendocrine tumors and metastatic prostate cancer, where conventional therapies have limited success. Advancements in radiopharmaceuticals, including isotopes like Lutetium-177 (Lu-177) and Actinium-225 (Ac-225), are enhancing the precision of cancer treatment while minimizing damage to healthy tissues.
Download a Free Sample To learn more about this report,
Alpha-Emitting Radioligands Are Emerging as the Next Generation of Targeted Radiation Therapy
The radioligand therapy market is moving beyond established beta-emitting treatments toward alpha-emitting radioligands that can deliver highly energetic radiation over a shorter distance. Actinium-225 is receiving particular attention because its alpha particles can cause strong tumor-cell damage while limiting radiation exposure to nearby healthy tissue. Developers are combining these isotopes with tumor-targeting ligands such as PSMA-directed molecules to explore treatments for patients with advanced cancers. This shift is broadening research beyond existing lutetium-177 products and encouraging investment in new isotopes, manufacturing technologies, and clinical programs. As development progresses, alpha emitters could create differentiated treatment options and expand the therapeutic capabilities of precision nuclear medicine.
in May 2026, Novartis reported promising Phase I results for its actinium-225-based PSMA radioligand therapy and confirmed that two Phase III trials of the investigational treatment were underway.
Earlier Use of Radioligand Therapy Is Expanding the Eligible Patient Population
Radioligand therapies are moving into earlier stages of cancer treatment, increasing the number of patients who may become eligible for targeted radioactive medicines. Initial use has often focused on heavily pretreated patients after multiple therapies have failed. Clinical evidence showing benefits earlier in the treatment pathway allows physicians to consider radioligand therapy before some conventional systemic treatments. This increases potential treatment volumes and encourages hospitals to build nuclear medicine capacity. Earlier use also strengthens demand for diagnostic imaging that confirms expression of therapeutic targets before treatment. As regulatory approvals expand treatment sequences, manufacturers gain a larger addressable population while healthcare providers require greater radiopharmaceutical production, imaging, treatment, and radiation-safety capabilities.
in March 2025, the U.S. FDA expanded Pluvicto's indication to PSMA-positive metastatic castration-resistant prostate cancer after ARPI treatment, allowing eligible patients to receive it before taxane-based chemotherapy.
Short Radioactive Lifetimes Create Complex Manufacturing and Distribution Requirements
Radioligand therapies face logistical restraints because radioactive isotopes lose activity continuously after production. Manufacturers must coordinate isotope generation, drug preparation, quality testing, transportation, hospital scheduling, and patient administration within tightly controlled timeframes. Unlike conventional medicines that can remain in warehouses for extended periods, many radiopharmaceutical doses must be manufactured for specific patients and delivered rapidly. Delays in production or transportation can therefore make doses unsuitable for treatment and disrupt clinical schedules. These requirements increase dependence on specialized manufacturing sites, licensed transportation networks, trained personnel, and reliable isotope supplies. Geographic distance from production facilities can further complicate access, making manufacturing location and distribution reliability important factors influencing commercial expansion.
in November 2025, Novartis opened a 10,000-square-foot radioligand therapy facility in Carlsbad, California, designed to serve the western United States, Alaska, and Hawaii while supporting an on-time delivery rate above 99.9%.
Expansion Into New Cancer Types Creates a Larger Development Opportunity
The ability to pair radioactive isotopes with different tumor-targeting molecules creates opportunities to expand radioligand therapy beyond currently established indications. Developers can design ligands against biomarkers expressed by different tumors and combine them with therapeutic radioisotopes, creating a flexible platform for precision oncology. Research programs are therefore exploring radioligands across prostate cancer and additional solid tumors while also investigating new isotopes and combination strategies. Successful development could substantially widen the patient population addressable by nuclear medicine and create demand for companion imaging, isotope production, specialized manufacturing, and treatment infrastructure. Companies with capabilities spanning target discovery, radiochemistry, clinical development, and isotope supply are positioned to capture opportunities as the therapeutic pipeline diversifies.
in January 2026, Novartis announced a new 35,000-square-foot radioligand therapy manufacturing facility in Winter Park, Florida, while highlighting pipeline development involving new isotopes, ligands, combinations, and additional cancer types.
Radiation Safety Requirements Make Treatment Infrastructure More Complex
Scaling radioligand therapy requires healthcare facilities to manage radioactive medicines safely throughout storage, preparation, administration, patient care, and waste handling. Hospitals need trained nuclear medicine physicians, radiopharmacists, technologists, medical physicists, radiation-protection professionals, and suitable treatment areas. Staff must control occupational exposure while ensuring patients receive the intended activity safely and consistently. Facilities also need procedures for contamination monitoring, radioactive waste, transportation, and emergency situations. These requirements can make treatment expansion more difficult than administering conventional oncology medicines, especially in hospitals without established nuclear medicine programs. Increasing patient volumes will therefore require investment not only in drug manufacturing but also in clinical infrastructure, professional training, standardized procedures, and radiation-safety systems.
in 2025, the ACR, ACNM, ARS, and SNMMI issued a dedicated practice parameter for PSMA therapy covering the safe clinical use of lutetium-177 PSMA-targeted treatment and emphasizing radiation protection and professional training requirements.
Actinium-225 (Ac-225) is Projected to Register the Fastest Growth at a CAGR of 20.4%
The Actinium-225 (Ac-225) segment is projected to register the fastest growth in the radioligand therapy market at a CAGR of 20.4% during the forecast period, supported by increasing interest in targeted alpha therapies for treating difficult-to-manage cancers. Actinium-225 can deliver highly localized alpha radiation to targeted cancer cells while limiting exposure to surrounding tissues. Expanding research into alpha-emitting radiopharmaceuticals, development of new targeted therapies, and increasing focus on precision oncology are strengthening the potential use of Actinium-225 in radioligand therapy.
Request Customizationto receive a tailored report.
Prostate-Specific Membrane Antigen Dominated the Market with 67.5% Share in 2025
The prostate-specific membrane antigen segment accounted for the largest share of the global radioligand therapy market at 67.5% in 2025, driven by its importance as a therapeutic target for prostate cancer. PSMA is highly expressed in many prostate cancer cells, allowing radioligands to selectively deliver radioactive isotopes to targeted tumor sites. Increasing adoption of PSMA-directed therapies, growing clinical research, and expanding interest in targeted treatment approaches for advanced prostate cancer continue to reinforce the segment's dominant position within radioligand therapy.
Prostate Cancer Dominated the Market with 61.8% Share in 2025
The prostate cancer segment accounted for the largest share of the global radioligand therapy market at 61.8% in 2025, supported by increasing application of targeted radiopharmaceutical therapies for patients with advanced disease. Radioligand therapy enables radioactive isotopes to be delivered selectively to cancer cells expressing specific molecular targets, helping provide targeted treatment while limiting unnecessary radiation exposure to surrounding tissues. Growing utilization of PSMA-targeted treatment approaches, expanding therapeutic options, and continued development of precision oncology strategies are strengthening the role of radioligand therapy in prostate cancer treatment.
Cancer Treatment Centers is Projected to Register the Fastest Growth at a CAGR of 17.2%
The cancer treatment centers segment is projected to register the fastest growth in the radioligand therapy market at a CAGR of 17.2% during the forecast period, supported by increasing availability of specialized oncology services and growing adoption of targeted radiopharmaceutical treatments. Cancer treatment centers provide dedicated infrastructure and multidisciplinary expertise required for patient selection, radiopharmaceutical administration, radiation safety, and post-treatment monitoring. Increasing integration of nuclear medicine with precision oncology and expanding availability of advanced cancer therapies continue to support radioligand therapy adoption across specialized cancer treatment centers.
Speak to an Analystto discuss market opportunities.
North America dominated the radioligand therapy market with the largest 42.6% market share in 2025, representing a market value of USD 1.41 billion. The region is projected to grow at a CAGR of 15.1% during the forecast period. Its leadership is supported by advanced oncology infrastructure, extensive nuclear medicine capabilities, growing adoption of targeted cancer treatments, and strong pharmaceutical research activities. Radioligand therapies combine targeting molecules with therapeutic radioisotopes to deliver radiation directly to specific cancer cells while limiting exposure to surrounding tissues. Expanding clinical use, development of specialized treatment centers, and continued investment in precision oncology strengthen North America’s position in the global radioligand therapy market.
The United States is an important contributor to the radioligand therapy market due to its advanced cancer treatment infrastructure, extensive nuclear medicine capabilities, and strong pharmaceutical and biotechnology industries. Hospitals and specialized oncology centers are increasingly integrating targeted radiopharmaceutical therapies into treatment pathways for selected cancers. Pharmaceutical companies are also developing new radioligand candidates targeting different tumor-associated biomarkers and cancer types. Expansion requires specialized facilities for isotope handling, treatment administration, radiation safety, and patient monitoring. Strong clinical research capabilities and growing interest in precision medicine continue to encourage development of targeted radioactive therapies, supporting the country's radioligand therapy market.
Canada contributes to the radioligand therapy market through its established healthcare system, nuclear research capabilities, oncology expertise, and growing interest in precision cancer treatments. Specialized medical centers use nuclear medicine technologies for cancer diagnosis and therapy, creating an important foundation for broader radioligand therapy adoption. Research organizations and healthcare institutions are exploring targeted radiopharmaceutical approaches that can deliver therapeutic radiation more precisely to cancer cells. Development of the market also depends on reliable radioisotope availability, specialized healthcare professionals, and appropriate treatment infrastructure. Continued advancement of nuclear medicine and oncology research supports long-term development of Canada's radioligand therapy market.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe is the fastest-growing region in the radioligand therapy market and is expected to expand at a CAGR of 17.3% during the forecast period. The region accounted for 28.4% of the global market in 2025, representing a market value of USD 0.94 billion. Growth is supported by established nuclear medicine infrastructure, increasing adoption of targeted oncology treatments, and expanding pharmaceutical development of radiopharmaceutical therapies. Healthcare providers are strengthening capabilities for handling therapeutic radioisotopes and delivering specialized cancer treatments. Growing clinical research and development of therapies targeting additional cancer biomarkers are broadening potential applications. These developments support expansion of the radioligand therapy market across Europe.
Germany is an important contributor to the radioligand therapy market in Europe due to its advanced healthcare infrastructure, established nuclear medicine expertise, and strong pharmaceutical and medical research ecosystem. Specialized hospitals and oncology centers have capabilities for administering radioactive treatments and monitoring patients receiving targeted therapies. Research institutions and industry participants are investigating radioligand approaches for treating different cancers based on specific molecular targets. Growing integration of diagnostic imaging with targeted therapeutic approaches is also supporting development of theranostic treatment strategies. Continued investment in oncology research, radiopharmaceutical development, and specialized nuclear medicine infrastructure strengthens Germany's position within the European radioligand therapy market.
The United Kingdom contributes to the radioligand therapy market through its established cancer research environment, nuclear medicine services, pharmaceutical development capabilities, and specialized healthcare infrastructure. Clinical institutions are increasingly evaluating targeted radiopharmaceutical therapies as part of precision oncology approaches. Radioligand therapy requires coordination among oncologists, nuclear medicine specialists, radiologists, pharmacists, and radiation safety professionals, encouraging development of multidisciplinary treatment capabilities. Research into new molecular targets and therapeutic radioisotopes is also expanding potential applications beyond currently established treatments. Continued advancement of precision medicine, cancer research, and radiopharmaceutical technologies supports the United Kingdom's contribution to the European radioligand therapy market.
Asia Pacific accounted for 19.7% of the global radioligand therapy market in 2025, reaching a market value of USD 0.65 billion. The region is anticipated to grow at a CAGR of 16.4% during the forecast period. Market development is supported by improving oncology infrastructure, expanding nuclear medicine capabilities, growing awareness of precision cancer therapies, and increasing healthcare investment. Hospitals and specialized treatment centers are strengthening their ability to deliver advanced radiopharmaceutical therapies. Growing pharmaceutical research and increasing availability of molecular imaging technologies are also supporting adoption. Continued modernization of cancer care and development of specialized treatment infrastructure support expansion of the radioligand therapy market across Asia Pacific.
Japan is an important contributor to the radioligand therapy market through its advanced healthcare system, sophisticated medical imaging capabilities, and strong pharmaceutical research environment. Nuclear medicine and molecular imaging provide an important foundation for identifying suitable patients and supporting targeted radiopharmaceutical treatment. Healthcare institutions are increasingly interested in precision oncology approaches that match therapies with specific biological characteristics of tumors. Development of additional radioligand treatments could broaden therapeutic options across selected cancer types. Strong capabilities in pharmaceutical research, medical technology, imaging, and oncology care support continued innovation. These factors strengthen Japan's contribution to the Asia Pacific radioligand therapy market.
China plays a significant role in the radioligand therapy market due to its expanding healthcare infrastructure, large oncology patient population, and increasing investment in advanced cancer treatment technologies. Hospitals and research institutions are strengthening nuclear medicine and molecular imaging capabilities that can support targeted radiopharmaceutical therapies. Pharmaceutical and biotechnology companies are also showing growing interest in precision oncology and innovative drug development approaches. Broader adoption requires expansion of specialized treatment facilities, reliable isotope supply, and trained nuclear medicine professionals. Continued healthcare modernization, oncology research, and development of advanced therapeutic technologies reinforce China's importance within the Asia Pacific radioligand therapy market.
Latin America represented 5.2% of the global radioligand therapy market in 2025, with a market value of USD 0.17 billion. The region is expected to register a CAGR of 13.8% during the forecast period. Growth is supported by improving oncology services, gradual expansion of nuclear medicine infrastructure, and increasing interest in advanced targeted cancer treatments. Specialized hospitals are developing capabilities to integrate sophisticated diagnostic and therapeutic technologies into cancer care. Increasing awareness of precision oncology and growing availability of radiopharmaceutical expertise are creating opportunities for broader treatment adoption. Continued modernization of healthcare infrastructure supports expansion of the radioligand therapy market across Latin America.
Brazil is an important contributor to the radioligand therapy market in Latin America due to its large healthcare system, established oncology sector, and existing nuclear medicine capabilities. Specialized cancer centers and hospitals provide a foundation for expanding targeted radiopharmaceutical treatments as advanced therapies become more accessible. Nuclear medicine infrastructure can support patient imaging, treatment planning, radioisotope handling, and therapeutic administration. Growing interest in precision oncology is encouraging healthcare providers and researchers to evaluate treatment approaches based on specific molecular targets. Continued development of cancer treatment facilities, specialist expertise, and radiopharmaceutical capabilities reinforces Brazil's importance within the regional radioligand therapy market.
The Middle East and Africa accounted for 4.1% of the global radioligand therapy market in 2025, representing a market value of USD 0.14 billion. The region is projected to expand at a CAGR of 12.9% during the forecast period. Market development is supported by improving oncology infrastructure, increasing investment in specialized healthcare facilities, and gradual expansion of nuclear medicine capabilities. Advanced hospitals are adopting sophisticated cancer diagnosis and treatment technologies, creating opportunities for targeted radiopharmaceutical therapies. Development of specialist expertise and reliable access to therapeutic radioisotopes will remain important for broader adoption. These factors support long-term development of the radioligand therapy market across the region.
The UAE contributes to the radioligand therapy market within the Middle East and Africa through its advanced healthcare infrastructure, investment in specialized oncology services, and increasing adoption of precision medicine technologies. Major healthcare facilities are strengthening capabilities in cancer imaging, nuclear medicine, and advanced therapeutic services, creating a supportive environment for radiopharmaceutical treatments. Radioligand therapy requires specialized handling procedures, multidisciplinary clinical expertise, and coordinated patient management, making advanced medical infrastructure particularly important. Growing focus on providing sophisticated cancer treatments domestically is encouraging development of specialized capabilities. Continued healthcare investment and oncology modernization strengthen the UAE's role in the regional radioligand therapy market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
LAMEA Lidocaine Market Size, Growth , 2026-2034
North America Neurodegenerative Disease Market Size, 2034
We are featured on:
sales@straitsresearch.com